Application of Existing and Emerging Biomarkers for Immuno-Oncology Across Tumor Types

Learn from the experts about current and emerging immuno-oncology biomarkers to guide selection of optimal cancer treatment across tumor types. Participate in the interactive CCO Webinar or watch the on-demand Webcast and download the slides. Listen to a podcast for answers to FAQs asked during the live Webinar.
John L. Marshall, MD
Program Director
Jamie E. Chaft, MD
Scot Niglio, MD

Podcast

Listen to John L. Marshall, MD; Jamie E. Chaft, MD; and Scot Niglio, MD, answer audience questions from a live CCO Webinar on biomarker testing and the impact on immunotherapy treatment for diverse solid tumors including the latest on PD-L1, dMMR/MSI-high, tumor mutation burden, and other emerging biomarkers.

John L. Marshall, MD
Program Director
Jamie E. Chaft, MD Scot Niglio, MD
Released: August 10, 2020
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue